Last reviewed · How we verify
TissueGene-C
TissueGene-C is a gene therapy that uses a viral vector to deliver the human hepatocyte growth factor (HGF) gene to the liver, promoting tissue repair and regeneration.
TissueGene-C is a gene therapy that uses a viral vector to deliver the human hepatocyte growth factor (HGF) gene to the liver, promoting tissue repair and regeneration. Used for Cirrhosis, Liver failure.
At a glance
| Generic name | TissueGene-C |
|---|---|
| Also known as | TG-C |
| Sponsor | Kolon TissueGene, Inc. |
| Drug class | Gene therapy |
| Target | HGF gene |
| Modality | Biologic |
| Therapeutic area | Liver disease |
| Phase | Phase 3 |
Mechanism of action
The HGF gene is introduced to the liver cells, where it is expressed and produces the HGF protein. This protein then stimulates the proliferation and migration of hepatocytes, promoting tissue repair and regeneration. This mechanism is particularly useful for treating liver diseases such as cirrhosis and liver failure.
Approved indications
- Cirrhosis
- Liver failure
Common side effects
- Hepatitis
- Liver enzyme elevation
Key clinical trials
- A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee (PHASE3)
- Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee (PHASE3)
- A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis (PHASE2)
- Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis (PHASE1)
- Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis (PHASE3)
- Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee (PHASE1)
- Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee (PHASE2)
- Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TissueGene-C CI brief — competitive landscape report
- TissueGene-C updates RSS · CI watch RSS
- Kolon TissueGene, Inc. portfolio CI